Mytelase

Generic name: Ambenonium chloride

Drug class: Cholinergic muscle stimulants

Dosage form: Tablet

Route of administration: Oral

Dose: The oral dose must be individualized according to the patient’s response. For moderately severe myasthenia gravis, 5 mg to 25 mg of MYTELASE three or four times daily is an effective dose. Some patients may require as much as 50 mg to 75 mg per dose.

Mechanism of action: Ambenonium chloride is a cholinesterase inhibitor that suppresses cholinesterase activity, leading to increased acetylcholine levels at neuromuscular junctions. This enhancement improves nerve impulse transmission to muscle fibers, thereby increasing muscle strength and reducing fatigue.

Drug usage cases:

• Treatment of myasthenia gravis

Drug contraindications:

• Hypersensitivity to ambenonium chloride or any other ingredients of MYTELASE
• Concurrent use with mecamylamine or other ganglionic blocking agents
• Routine administration of atropine with MYTELASE is contraindicated

Side effects:

• Excessive gastrointestinal stimulation (e.g., abdominal cramps, diarrhea, vomiting)
• Excessive salivation
• Pallor
• Frequent urination
• Blurred vision
• Fasciculation and paralysis of voluntary muscles, including those of the tongue (thick tongue and difficulty in swallowing), shoulder, neck, and arms
• Rarely, generalized malaise and vertigo
• Miosis (constriction of the pupils)
• Increase in blood pressure with or without bradycardia
• Subjective sensations of internal trembling, and often severe anxiety and panic

Warnings:

• Due to its prolonged action, simultaneous administration with other cholinergics is contraindicated except under strict medical supervision
• Overdosage can lead to serious toxic effects; caution is essential when increasing the dosage
• Use with caution in patients with asthma, Parkinson’s disease, or mechanical intestinal or urinary obstruction

Use during pregnancy or breastfeeding:

Safe use of MYTELASE during pregnancy has not been established. Therefore, before use in pregnant women or women of childbearing potential, the potential benefits should be weighed against possible risks to mother and fetus. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from MYTELASE, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.